Veronica Troutner Baarson

Molecular Oncology Specialist Michigan @Agendia

MI, US

Negotiate, strategize and develop relationships with KOL, providers, and clinical staff for use of Agendia early invasive breast cancer in Michigan & Indiana. Agendia MammaPrint and BluePrint 150 gene personalized molecular profile provides insight on a patient at the genomic level. The physician can evaluate the risk score and examine the activity of specific genes inside a tumor – how they interact to drive the behavior of a tumor. By pairing these insights with clinical factors, we can more comprehensively understand a woman’s unique cancer and more confidently plan for the patient next steps of treatment. Agenida has 20+ years of clinical validation. 200 research collaborations. 100s of publications. Our https://agendia.com/ongoing-trials/ FLEX Study, SWOG S2206, INSIGHT Trial, DEBRA Trial, LESS Study and PROOFS.

Spring Arbor University

Bachelor of Arts - BA